Outcomes of Laparoscopic Sleeve Gastrectomy

Not Applicable

Completed

• Conditions: Bariatric Surgery Candidate; Laparoscopic Sleeve Gastrectomy; Obesity, Morbid
• Interventions: Procedure: Laparoscopic sleeve gastrectomy

• Registration Number: NCT03983122
• Lead Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Brief Summary

The aim of this study is to assess 5 year long-term outcomes of laparoscopic sleeve gastrectomy emphasizing weight loss and modification of comorbidities such as type 2 diabetes mellitus, hypertension and gastroesophageal reflux disease from a developing country, Turkey. Prospectively-collected patient data will retrospectively reviewed. To measure the efficacy of the procedure, we will calculate the excess weight loss percentage (EWL %). Effective weight loss after LSG will accepted as more than 50%. The changes in the status of the type 2 diabetes mellitus, hypertension, gastroesophageal reflux disease will be observed.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-08-01
• Primary Completion: 2013-12-01
• Study Completion: 2018-12-01
• Study First Submitted: 2019-05-25
• Status Verified: 2019-06
• Study First Submitted QC: 2019-06-10
• Last Update Submitted: 2019-06-10
• Study First Posted: 2019-06-12
• Last Update Posted: 2019-06-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Inclusion criteria were, patients between 18 to 65 years old, initial body mass index (BMI) 40 kg/m2 or BMI of 35 kg/m2 in the presence of additional comorbidity and failure of conservative treatment for 2 years.

Exclusion Criteria

• None

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Study group	Laparoscopic sleeve gastrectomy	Patients who undergo laparoscopic sleeve gastrectomy

Primary Outcome Measures

Name	Time	Method
Weight loss	5 years	Weight loss after surgery

Secondary Outcome Measures

Name	Time	Method
Remision of comorbid diseases	5 years	The pharmacological treatment status of comorbidities related to obesity of type 2 diabetes (T2DM) and hypertension and gastroesophageal reflux will be observed with questions about "did it stop after surgery (improvement), did the dose or number of medications used reduce (resolution), or were there no changes?"